2022-06-08 | NDAQ:APYX | Press release

Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apyx Medical Corporation (“Apyx” or “the Company”) (NASDAQ: APYX) for violation of §§10 (b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the United States Securities and Exchange Commission.

Investors who purchased the Company’s securities between May 12, 2021 and March 11, 2022 inclusive (the “Class Period”) are invited to contact the Company before August 5, 2022.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us via the firm’s website at www.schallfirm.com or by e-mail at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to do nothing, you can remain an absent member of the group.

According to the complaint, the company made false and misleading statements to the market. Apyx’s Advanced Energy products were frequently used for off-label indications, representing a significant portion of its sales. These off-label uses have led to an increase in the number of adverse event reports filed by the Company. This was likely to lead to regulatory scrutiny. Based on these facts, the company’s public statements were false and materially misleading throughout the Class Period. When the market learned the truth about Apyx, investors suffered damage.

Join the case to recoup your losses.

Schall Law Firm represents investors worldwide and specializes in securities class action and shareholder rights litigation.

This press release may be considered attorney advertising in certain jurisdictions under applicable law and ethics rules.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220608005748/en/